Drug Trial Radar · NCT06118281
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Jun 25, 2024
Primary completion
Jan 29, 2027
Study completion Jan 29, 2027
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- Collaborators
- Duke Clinical Research Institute
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.
Conditions
- Cardiovascular Risk
- Acute Myocardial Infarction (AMI)
Interventions
ZiltivekimabDrug
Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
PlaceboDrug
Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal strokeTime frame: From randomisation (month 0) to end-of-study (up to 25 months)
Locations
836 sites in 24 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular, LLC
Alexander City, Alabama
Birmingham VA Medical Center
Birmingham, Alabama
Grandview Medical Center
Birmingham, Alabama
Eastern Shore Rsrch Inst, LLC
Fairhope, Alabama
Heart Center Rsrch_Hunstville
Huntsville, Alabama
Mobile Heart USA Health Cardiology Clinic
Mobile, Alabama
Mercy Gilbert Medical Center
Gilbert, Arizona
Mayo Clinic Arizona
Phoenix, Arizona
Honor Health
Scottsdale, Arizona
Arkansas Cardiology Clinic
Little Rock, Arkansas
Central Arkansas Veteran's Healthcare System
Little Rock, Arkansas
Valley Clinical Trials
Covina, California
UCSD Medical Center
La Jolla, California
Loma Linda University Faculty Medical Clinics
Loma Linda, California
VAGrtrLosAngelesHlthcareSystem
Los Angeles, California
University of Californ LA-UCLA
Los Angeles, California
University Of California Irvine
Orange, California
Kaiser Permanente Viewridge Medical Offices
San Diego, California
San Diego Cardiac Center
San Diego, California
San Francisco V.A. Medical Center
San Francisco, California
LA BioMed Harbor UCLA Med Cenr
Torrance, California
Torrance Memorial Medical Center
Torrance, California
Interventional Cardiology Medical Group
West Hills, California
University of CO - Division of Cardiology
Aurora, Colorado
Denver Health Medical Center
Denver, Colorado
Colorado Heart and Vascular PC
Golden, Colorado
S Denver Cardiology Associates
Littleton, Colorado
Advanced Heart & Vein Center
Thornton, Colorado
Bridgeport Hospital
Bridgeport, Connecticut
Danbury Hospital - Cardiology Department
Danbury, Connecticut
Yale Ctr for Clin Invest
New Haven, Connecticut
Cardiology Associates of Fairfield County
Stamford, Connecticut
Christiana Care Health Services, Inc.
Newark, Delaware
MedStar Hlth Res Institute
Washington D.C., District of Columbia
Holy Cross Hospital
Fort Lauderdale, Florida
University of Florida
Gainesville, Florida
Memorial Healthcare
Hollywood, Florida
UF Hlth Jacksonville
Jacksonville, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
Baptist Heart Specialists
Jacksonville, Florida
Showing 40 of 836 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.